A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.

NCT03545971 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: IBI310
DRUG: Sintilimab

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.